The PennZone

  • Home
  • Non-profit
  • Books
  • Health
  • Marketing
  • Entertainment
  • Business
  • Sports
  • Legal

SafER has announced a Stage 3 clinical trial evaluating the SafER Negative Pressure System reducing aerosol emissions during bronchoscopic procedures
The PennZone/10271927

Trending...
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
Vacuum And Mask Respiratory Shield Endo Shield Hospital Nosuction 1 Hospital Suction 1c SafER Medical Products LLC
BRANSON, Mo. - PennZone -- Bronchoscopy is known to be an aerosol generating procedure and produce plumes of microscopic particles, some of which may carry infectious airborne organisms, that can then be inhaled by medical personnel in attendance and subsequently pose a high-risk of those medical staff contracting the disease.  "Our goal since the beginning of the pandemic has been to create a safer work environment for our friends and colleagues who are exposed to dangerous pathogens when performing aerosol generating procedures, while expanding access to those life-saving procedures for our patients", said SafER Chief Medical Officer, Dr. Rick Blubaugh.

The SafER system is the world's first portable negative pressure system that utilizes HEPA filtration to capture dangerous fugitive emissions at the source – the patient.  The system has been in use since the pandemic in hospitals, ambulances, and long-term facilities around the country and can be utilized during a variety of procedures including intubation, nebulizer, CPAP or Bi-Level PAP, endoscopy, and sputum or swab collection.

More on The PennZone
  • Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
  • P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England

The study is randomized controlled and will take place in a 1,000-bed tertiary facility and is expected to enroll 80 patients over a 3-month period.  The goals of the study are to assess the system and the reduction of aerosol emissions produced during bronchoscopic procedures.  Results of the study are expected to be announced late this summer.

http://www.safermedicalproducts.com

Contact
Carl Baker
cbaker@safermedicalproducts.com


Source: SafER Medical Products LLC
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
  • Bridging Canvas and Cosmos: How Bioengineer Farin DeBose Captured the Essence of "True Science"
  • RPP to host first Professional Padel Week in Miami and announce the 2026 USA Awards winners
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs
  • NAO Releases Shopping Intelligence to Streamline Your Quest for Value
  • International Misophonia Foundation Launches Sensory Accessible Technology Initiative to Address Overlooked Digital Accessibility Barriers
  • The Robert Travers Team of Long & Foster Marks 300+ Homes Sold, Expands Seller Representation
  • CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • MoMojo Records Signs Gary Nicholson
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director

Popular on PennZone

  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia - 210
  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 103
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of - 101
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources

Similar on PennZone

  • TrueNorth Wellness Services Expands Rural Behavioral Health Care in Fulton County with Technology
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • Ten Ten Ten Announces Maximizing Quality Performance, a Value-Based Care Implementation Guide
  • Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
  • CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us